01 — What is it?
GHK-Cu has been studied for skin remodeling, collagen-related signaling and wound-healing biology. Human cosmetic/topical studies exist, but broad therapeutic claims remain unproven.
Database / Research Profiles / GHK-Cu
RESEARCH PROFILE
GHK-CU
Copper tripeptide complex • glycyl-L-histidyl-L-lysine + Cu²⁺
Skin / tissue remodelingPreclinical + limited topical human evidence
EVIDENCE SNAPSHOTPRECLINICAL + LIMITED TOPICAL HUMAN EVIDENCE
A 2006 randomized topical study after CO₂ laser resurfacing did not show significant objective improvements across several endpoints, although questionnaire-based skin-quality improvement was reported.
Research-first: This profile summarizes published evidence and regulatory context. It is educational reference material, not a diagnosis, treatment recommendation, or personalized dosing protocol.
02 — Research category
Skin / tissue remodeling. Evidence strength is based on the availability and quality of human clinical data, not on popularity in the research-peptide market.
03 — Evidence map
Human evidence: LIMITED / NONEPreclinical evidence: YESPersonal dosing protocol: NOT PROVIDED
A 2006 randomized topical study after CO₂ laser resurfacing did not show significant objective improvements across several endpoints, although questionnaire-based skin-quality improvement was reported.
04 — Mechanism / biology
GHK-Cu has been studied for skin remodeling, collagen-related signaling and wound-healing biology. Human cosmetic/topical studies exist, but broad therapeutic claims remain unproven.
05 — Safety & limitations
Safety depends on the exact molecule, formulation, route, dose, indication and study population. Research-market products may differ in identity, purity, sterility or stability from materials used in published trials. Absence of reported adverse events in a small study does not establish long-term safety.
06 — Regulatory context
Regulatory status varies by compound and jurisdiction. Where an approved product exists, its approval applies only to specified formulations and indications. Investigational or research-market status should not be presented as equivalent to approval.